Exenatide outperforms detemir in A1C reduction

01/11/2013 | DailyRx.com

Data on 216 diabetes patients showed 44.1% of those who took exenatide once a week attained an A1C of 7% or less, compared with only 11.4% in those who had insulin detemir treatment. Researchers also found patients in the exenatide group lost about 6 pounds, compared with a gain of about 1.8 pounds in the detemir group. The results appear in Diabetes Care.

View Full Article in:

DailyRx.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT